Rafael Reports Phase 3 Trappsol Cyclo Data In NPC
(RTTNews) - Wednesday, Rafael Holdings (RFL) reported topline results from the pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo in patients with Niemann-Pick Disease Type C (NPC).
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.